TP53 and neoplasm: When the results were aggregated across all subtypes, tumours with germline or somatic BRCA mutations and tumours with TP53 somatic mutations had significantly higher HR deficiency scores compared to wild-type tumours (p < 1e−5, Fig. 1c).